DrugDashboards

Tazarotene

tazarotene · TAZAROTENE .5 mg/g · Cream · Topical · Padagis Israel Pharmaceuticals Ltd

NDC 45802-0706-94 · 1 TUBE in 1 CARTON / 30 g in 1 TUBE · ANDA · View full market →

The short version

6 companies supply this market — a reasonable cushion if one runs into trouble. The price has fallen 35% in a year, to $6.72 per gram — and generics that get this cheap tend to get abandoned rather than defended. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$6.72per GMinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$3.95per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$10.71per unitnegotiated price across 2,747 plans — before rebates · Apr 1, 2026

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$10.71per unit
middle half $7.77$12.95 · 2,747 plans · Apr 1, 2026
Est. net of rebates
≈ $10.71
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
50%of plans cover it
tier 4 · prior auth 92% · step therapy 1% · qty limit 64%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 6 quarters since 2024.

NADAC price per unit

$0$5.00$10.00$15.00Dec 2024Sep 2026$6.72
22 price points · per GMSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$431.69
Reported to Texas DSHS · 2025 annual filing · Padagis Israel Pharmaceuticals Ltd

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$418,711
1,287 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

8Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • price down 32% year over year+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for tazarotene (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA217075
TE code
AB
Approval date
Jul 15, 2024
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of tazarotene (Cream)

LabelerStrengthFirst seenLast seen
Sun Pharmaceutical Industries, Inc.TAZAROTENE 1 mg/gJul 15, 2026Sep 3, 2026
Almirall, LLCTAZAROTENE .1 mg/gJul 15, 2026Sep 2, 2026
Almirall, LLCTAZAROTENE .05 mg/gJul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTAZAROTENE .5 mg/gJul 15, 2026Sep 2, 2026
Cosette Pharmaceuticals, Inc.TAZAROTENE 1 mg/gJul 15, 2026Sep 2, 2026
Cosette Pharmaceuticals, Inc.TAZAROTENE .5 mg/gJul 15, 2026Sep 2, 2026
Mayne PharmaTAZAROTENE 1 mg/gJul 15, 2026Sep 2, 2026
Padagis Israel Pharmaceuticals LtdTAZAROTENE .5 mg/gJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Tazarotene — NDC 45802-0706-94," retrieved September 3, 2026, https://drugdashboards.com/drug/45802070694.

Free to cite with attribution — see how the data is put together.